NCT02395978View on ClinicalTrials.gov

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 10, 2015

Primary Completion Date

March 12, 2019

Study Completion Date

March 18, 2019

Conditions
Major Depressive Disorder
Interventions
DRUG

PDC-1421 Capsule

PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.

DRUG

placebo

Placebo contained corn starch.

Trial Locations (5)

94305

Stanford Depression Research Clinic, San Francisco

Unknown

Taipei Veterans General Hospital, Taipei

Tri-Service General Hospital, Neihu Main Facility, Taipei

Wan Fang Hospital, Taipei

Linkou Chang Gung Memorial Hospital, Taoyuan District

All Listed Sponsors
lead

BioLite, Inc.

INDUSTRY

NCT02395978 - A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter